$1.10
+0.04(4.25%)
Mkt Cap $46M
$0.80
$2.02
52-Week Range
At a Glance
AI-generatedMIRA Pharmaceuticals reported a net loss of $10.4 million for fiscal year 2025, reflecting the capital-intensive nature of advancing its clinical-stage neuroscience pipeline.
8-K
MIRA Pharmaceuticals reported preclinical data showing Mira-55 produced no THC- or rimonabant-associated CNS side effects, including no psychogenic effects, sedation, catalepsy, motor impairment, or anxiogenic effects at oral doses of 10, 30, and 100 mg/kg. These results build on prior morphine-comparable pain relief in inflammatory pain models without opioid risks, supporting planned IND submission for inflammatory pain.$46M
Market Cap
—
Revenue
-$62M
Net Income
Employees2
Fundamentals
How The Business Makes Money
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
Industry Drug Manufacturers - General
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001904286
ISINUS60458C1045
CUSIP60458C104
Phone737-289-0835
Address855 North Wolfe Street, Baltimore, MD, 21205, US
SEC EDGAR